Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient herb takes on hypertension: new trial begins

NCT ID NCT07607275

Disease control Sponsor: Beijing Anzhen Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether Yufeng Ningxin, a traditional Chinese medicine, can safely lower blood pressure in adults with mild hypertension. About 350 people aged 18-65 with untreated or washed-out high blood pressure will receive either the herbal tablet or a placebo for 8 weeks. The main goal is to see if it reduces systolic blood pressure more than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female participants aged 18-65 years; 2. Newly diagnosed, untreated hypertension or treated hypertension with a seated systolic blood pressure of 140-159 mmHg and a daytime mean ambulatory systolic blood pressure ≥135 mmHg, following a ≥2-week washout of background antihypertensive medications; 3. The patient is capable of understanding the study requirements, is willing and able to comply with study procedures, and has provided written informed consent. Exclusion Criteria: 1. Secondary hypertension (including, but not limited to, renovascular hypertension, pheochromocytoma, primary aldosteronism, Cushing syndrome, aortic coarctation, or due to known history of moderate-to-severe obstructive sleep apnea); 2. Orthostatic hypotension (symptomatic or asymptomatic); 3. Participation in another hypertension-related clinical trial at enrollment or within 6 months prior; 4. Currently taking, taken within 30 days prior to randomization, or anticipated to receive during the study treatment period any medication or herbal supplement known to significantly affect blood pressure (with the exception of medications for the treatment of essential hypertension). These drugs include, but are not limited to: organic nitrates, glucocorticoids (excluding topical or inhaled corticosteroids), central nervous system stimulants (e.g., methylphenidate, dexmethylphenidate, amphetamines), estrogens, monoamine oxidase inhibitors, digitalis preparations, Chinese proprietary medicines (such as Tianma Gouteng Granules, Songling Xuemaikang Capsules, Yangxue Qingnao Granules), and herbal medicines (including Salvia miltiorrhiza, Uncaria rhynchophylla, Ginkgo biloba leaves, Prunella vulgaris, etc.); 5. Users of prescription non-steroidal anti-inflammatory drugs (NSAIDs); initiation of, changes to, or discontinuation of sodium-glucose co-transporter (SGLT2) inhibitor therapy within 4 weeks prior to screening. Patients who were stably taking an SGLT2 inhibitor or low-dose aspirin (defined as ≤100mg per day) for at least 4 weeks prior to screening with no anticipated changes during the study are permitted; 6. Severe hepatic or renal diseases (ALT \>3 times the upper limit of normal value, or end stage renal disease on dialysis, or eGFR \<30 mL/min/1.73 m2); 7. Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c\>9.0%); 8. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack \[TIA\]); 9. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 6 months; 10. Sustained atrial fibrillation or arrhythmias interfering with electronic BP measurement; 11. NYHA class III-IV heart failure, or hospitalization for chronic heart failure exacerbation within the past 6 months; 12. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period; 13. Dilated cardiomyopathy, hypertrophic cardiomyopathy, rheumatic heart disease, or congenital heart disease; 14. Other severe diseases that may affect participant enrollment or survival, such as malignancy or acquired immunodeficiency syndrome (AIDS); 15. Cognitive impairment or severe neuropsychiatric comorbidities that render the patient incapable of providing informed consent; 16. Participants preparing for or under pregnancy and/or lactation; 17. Frequent night-shift work, with primary working hours during nighttime (e.g., 8:00 PM to 8:00 AM); 18. Other conditions deemed inappropriate for participation by the investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential (primary) hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Essential (primary) hypertension Hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Anzhen Hospital

    RECRUITING

    Beijing, China

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, China

  • First Hospital of Shanxi Medical University

    NOT_YET_RECRUITING

    Taiyuan, China

  • Fuwai Hospital, Chinese Academy of Medical Sciences

    NOT_YET_RECRUITING

    Beijing, China

  • Inner Mongolia People's Hospital

    NOT_YET_RECRUITING

    Hohhot, China

  • Jiangsu Province Hospital

    NOT_YET_RECRUITING

    Nanjing, China

  • Longyan First Hospital

    NOT_YET_RECRUITING

    Longyan, China

  • Luohe Central Hospital

    RECRUITING

    Luohe, China

  • Peking University First Hospital

    NOT_YET_RECRUITING

    Beijing, China

  • Renmin Hospital of Wuhan University

    NOT_YET_RECRUITING

    Wuhan, China

  • The First Affiliated Hospital of Chongqing Medical University

    NOT_YET_RECRUITING

    Chongqing, China

  • The First Affiliated Hospital of Xiamen University

    RECRUITING

    Xiamen, China

  • The Second Affiliated Hospital of Dalian Medical University

    RECRUITING

    Dalian, China

  • The Second Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, China

  • The Second Affiliated Hospital of Shantou University Medical College

    NOT_YET_RECRUITING

    Shantou, China

  • Tianjin Kanghui Hospital

    RECRUITING

    Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.